Kenneth R. Peak Brain & Pituitary Treatment Center
U.S. PATIENTS:713.441.8500
INTERNATIONAL PATIENTS:+1.713.441.2340
Novel Gene Therapy Treatment
Surviving and Thriving After Gene Therapy
Now, 1 year and 4 months later, Stratton is a 2020 graduate from Texas A&M Galveston.
Learn more about our gene therapy clinical trial at the Peak Center
Treating Glioblastoma With Innovative Gene Therapy
First Patient In The World Receives Gene Therapy Re-Treatment
Today, over 2 years and 3 months later, Ed is the first patient in the world to be re-treated with the experimental gene therapy and he continues to defy the odds.
Gene Therapy Results In The Longest Living Survivor At Houston Methodist
Matt Futer was given less than 3 months to live when he was initially diagnosed with glioblastoma. After successful treatment of the experimental gene therapy, Matt has been cancer free for over 7 years.
Oncomagnetics: A New Experimental Treatment for Brain Cancer
The Peak Center has developed an experimental magnetic device in the form of an easily wearable and removable helmet. It generates targeted, oscillating frequencies and patterns that have been shown to destroy brain cancer by targeting and disrupting dysfunctional energy production in the cancer cells.
Patients do not have to shave their heads and only 6 hours of treatment time is required per day.
Request more information on this experimental treatment here.
David Baskin, MD Discusses The Benefits Offered At The Peak Center
Learn how the Kenneth R. Peak Brain & Pituitary Tumor Treatment Center combines cutting-edge surgical technology, state-of-the-art research protocols and highly skilled physicians and nurses to provide personalized and compassionate care for patients.
Novel Research
Novel Gene Therapy Shows Early Promise Against Glioblastoma
How do you handle risk?
Experimental glioblastoma therapy shows curative powers in mice models
Houston Methodist researchers found mice harboring human glioblastoma tumors in their brains had greatly enhanced survival when given a newly developed prodrug that targets and destroys the DNA inside the glioblastoma cell mitochondria, leaving normal cells intact. Learn more.